The company's products include dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The company operates with limited financial visibility and faces significant stock price volatility; the share price declined from $2.90 in March 2025 to $0.63 in March 2026, representing a 78.29% decline.
Cyborg Score Rationale
China Pharma faces severe operational and financial headwinds. Substantial stock price deterioration (78% decline in one year as of March 2026), multiple NYSE American compliance deficiency notices, and sparse positive developments signal distressed fundamentals. Limited analyst coverage and recent patent acquisitions suggest efforts to stabilize operations.
Top Insights
(March 2026) Stock price collapsed 78% year-over-year, falling from $2.90 to $0.63 per share
(January 2026) Stockholders approved reverse stock split and governance changes
(December 2025) Acquired Ipragliflozin Patent via stock issuance
Company faces ongoing NYSE American listing compliance challenges due to stockholders' equity deficiency and historical net losses
Named Competitors
Generic Pharmaceuticals — China's largest pharmaceutical producer and distributor
Branded Pharmaceuticals — Specialty pharmaceutical manufacturer in China
Specialty Injectables — Chinese injectable pharmaceutical manufacturer
Recent Developments
(May 2026) NYSE American inquired about unusual market activity; company disclosed no material nonpublic information
(January 2026) Stockholders approved reverse stock split and governance changes
(December 2025) Acquired Ipragliflozin Patent via stock issuance
Open the full interactive China Pharma Holdings, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.